203 related articles for article (PubMed ID: 32124316)
1. In Silico Prediction of Tumor Neoantigens with TIminer.
Kirchmair A; Finotello F
Methods Mol Biol; 2020; 2120():129-145. PubMed ID: 32124316
[TBL] [Abstract][Full Text] [Related]
2. TIminer: NGS data mining pipeline for cancer immunology and immunotherapy.
Tappeiner E; Finotello F; Charoentong P; Mayer C; Rieder D; Trajanoski Z
Bioinformatics; 2017 Oct; 33(19):3140-3141. PubMed ID: 28633385
[TBL] [Abstract][Full Text] [Related]
3. ProGeo-neo: a customized proteogenomic workflow for neoantigen prediction and selection.
Li Y; Wang G; Tan X; Ouyang J; Zhang M; Song X; Liu Q; Leng Q; Chen L; Xie L
BMC Med Genomics; 2020 Apr; 13(Suppl 5):52. PubMed ID: 32241270
[TBL] [Abstract][Full Text] [Related]
4. OpenVax: An Open-Source Computational Pipeline for Cancer Neoantigen Prediction.
Kodysh J; Rubinsteyn A
Methods Mol Biol; 2020; 2120():147-160. PubMed ID: 32124317
[TBL] [Abstract][Full Text] [Related]
5. Applications of Next-Generation Sequencing in Neoantigen Prediction and Cancer Vaccine Development.
Lancaster EM; Jablons D; Kratz JR
Genet Test Mol Biomarkers; 2020 Feb; 24(2):59-66. PubMed ID: 30907630
[TBL] [Abstract][Full Text] [Related]
6. pTuneos: prioritizing tumor neoantigens from next-generation sequencing data.
Zhou C; Wei Z; Zhang Z; Zhang B; Zhu C; Chen K; Chuai G; Qu S; Xie L; Gao Y; Liu Q
Genome Med; 2019 Oct; 11(1):67. PubMed ID: 31666118
[TBL] [Abstract][Full Text] [Related]
7. Toward in silico Identification of Tumor Neoantigens in Immunotherapy.
Zhou C; Zhu C; Liu Q
Trends Mol Med; 2019 Nov; 25(11):980-992. PubMed ID: 31494024
[TBL] [Abstract][Full Text] [Related]
8. Genomic prediction of neoantigens: immunogenomics before NGS.
Mardis ER
Nat Rev Genet; 2021 Sep; 22(9):550-551. PubMed ID: 33990775
[No Abstract] [Full Text] [Related]
9. Next-generation sequencing technologies accelerate advances in T-cell therapy for cancer.
Yin Q; Tang J; Zhu X
Brief Funct Genomics; 2019 Mar; 18(2):119-128. PubMed ID: 29982317
[TBL] [Abstract][Full Text] [Related]
10. TSNAD and TSNAdb: The Useful Toolkit for Clinical Application of Tumor-Specific Neoantigens.
Wu J; Zhou Z
Methods Mol Biol; 2023; 2673():167-174. PubMed ID: 37258913
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive profiling of cancer neoantigens from aberrant RNA splicing.
Wickland DP; McNinch C; Jessen E; Necela B; Shreeder B; Lin Y; Knutson KL; Asmann YW
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38754917
[TBL] [Abstract][Full Text] [Related]
12. Strength in Numbers: Identifying Neoantigen Targets for Cancer Immunotherapy.
Kishton RJ; Lynn RC; Restifo NP
Cell; 2020 Oct; 183(3):591-593. PubMed ID: 33125888
[TBL] [Abstract][Full Text] [Related]
13. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
[TBL] [Abstract][Full Text] [Related]
14. Bioinformatic methods for cancer neoantigen prediction.
Boegel S; Castle JC; Kodysh J; O'Donnell T; Rubinsteyn A
Prog Mol Biol Transl Sci; 2019; 164():25-60. PubMed ID: 31383407
[TBL] [Abstract][Full Text] [Related]
15. Prediction and prioritization of neoantigens: integration of RNA sequencing data with whole-exome sequencing.
Karasaki T; Nagayama K; Kuwano H; Nitadori JI; Sato M; Anraku M; Hosoi A; Matsushita H; Takazawa M; Ohara O; Nakajima J; Kakimi K
Cancer Sci; 2017 Feb; 108(2):170-177. PubMed ID: 27960040
[TBL] [Abstract][Full Text] [Related]
16. CloudNeo: a cloud pipeline for identifying patient-specific tumor neoantigens.
Bais P; Namburi S; Gatti DM; Zhang X; Chuang JH
Bioinformatics; 2017 Oct; 33(19):3110-3112. PubMed ID: 28605406
[TBL] [Abstract][Full Text] [Related]
17. Population-level distribution and putative immunogenicity of cancer neoepitopes.
Wood MA; Paralkar M; Paralkar MP; Nguyen A; Struck AJ; Ellrott K; Margolin A; Nellore A; Thompson RF
BMC Cancer; 2018 Apr; 18(1):414. PubMed ID: 29653567
[TBL] [Abstract][Full Text] [Related]
18. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.
Schrörs B; Lübcke S; Lennerz V; Fatho M; Bicker A; Wölfel C; Derigs P; Hankeln T; Schadendorf D; Paschen A; Wölfel T
Oncotarget; 2017 Apr; 8(17):28312-28327. PubMed ID: 28423700
[TBL] [Abstract][Full Text] [Related]
19. NeoPredPipe: high-throughput neoantigen prediction and recognition potential pipeline.
Schenck RO; Lakatos E; Gatenbee C; Graham TA; Anderson ARA
BMC Bioinformatics; 2019 May; 20(1):264. PubMed ID: 31117948
[TBL] [Abstract][Full Text] [Related]
20. Immunogenic peptide discovery in cancer genomes.
Snyder A; Chan TA
Curr Opin Genet Dev; 2015 Feb; 30():7-16. PubMed ID: 25588790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
